Eli Lilly's Oral GLP-1 Beats Wegovy
Eli Lilly's investigational oral weight-loss drug, orforglipron, outperformed Novo Nordisk's oral Wegovy in a head-to-head trial. The results showed superior reductions in both A1c and body weight, escalating the pharma arms race for a convenient pill to tap the massive chronic disease market. This win positions Lilly's candidate as the likely new standard, pressuring a field of competitors like Pfizer and Amgen to accelerate their own oral drug development.
In the head-to-head ACHIEVE-3 trial, the 36 mg dose of orforglipron reduced A1C by 1.9 percentage points and body weight by nearly 8% after one year. This compares to a 1.5 point A1C reduction and just over a 5% weight loss for the highest dose of oral semaglutide. Orforglipron's key advantage lies in its structure; it is a non-peptide, small-molecule agonist. This design allows it to be taken like a conventional pill without the strict food and water restrictions required for oral semaglutide, which must be taken on an empty stomach 30 minutes before the first meal of the day. The total market for anti-obesity medications is forecast to reach between $60 billion and $82.5 billion by 2030-2032, with the convenient oral segment projected to hit $9.1 billion by 2036. This massive potential explains the intense R&D focus from major pharmaceutical
